News
NERV
6.07
-6.18%
-0.40
Weekly Report: what happened at NERV last week (0420-0424)?
Weekly Report · 4d ago
Minerva Neurosciences files Form 3 for Chief Business Officer and GC James Joseph O'Connor
PUBT · 04/22 20:54
Weekly Report: what happened at NERV last week (0413-0417)?
Weekly Report · 04/20 10:00
Minerva launched with New Outperform at Citizens on schizophrenia candidate
Seeking Alpha · 04/15 15:57
Minerva Neurosciences Initiated at Market Outperform by Citizens
Dow Jones · 04/15 13:29
Minerva Neurosciences Price Target Announced at $14.00/Share by Citizens
Dow Jones · 04/15 13:29
Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14
Benzinga · 04/15 13:18
Minerva initiated with an Outperform at Citizens
TipRanks · 04/15 08:40
Weekly Report: what happened at NERV last week (0406-0410)?
Weekly Report · 04/13 10:03
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
TipRanks · 04/06 21:48
Minerva Neurosciences announces upcoming annual shareholder meeting
Reuters · 04/06 21:08
Weekly Report: what happened at NERV last week (0330-0403)?
Weekly Report · 04/06 10:04
Minerva Neurosciences Appoints New Chief Business Officer, Counsel
TipRanks · 04/02 21:51
Minerva appoints Jim O’Connor as chief business officer
TipRanks · 04/02 20:10
*Minerva Neurosciences: Geoff Race, the Company's Pres, Has Elected to Leave the Co >NERV
Dow Jones · 04/02 20:08
*Minerva Neurosciences: Appoints Jim O'Connor as Chief Business Officer, Effective April 21 >NERV
Dow Jones · 04/02 20:08
Minerva appoints Jim O'Connor chief business officer as President Geoff Race exits
Reuters · 04/02 20:05
MINERVA ANNOUNCES LEADERSHIP TRANSITION
Reuters · 04/02 20:05
Press Release: Minerva Announces Leadership Transition
Dow Jones · 04/02 20:05
Minerva screens first patient in roluperidone trial
TipRanks · 03/31 20:21
More
Webull provides a variety of real-time NERV stock news. You can receive the latest news about Minerva Neurosci through multiple platforms. This information may help you make smarter investment decisions.
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.